檢索結果 - Hieu, Nguyen Dinh
- Showing 1 - 4 results of 4
-
1
-
2
-
3
OP40 PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study Results 由 Bruce E. Sands, Laurent Peyrin–Biroulet, Silvio Danese, David T. Rubin, Séverine Vermeire, O Laurent, Allison Luo, Hieu Nguyen Dinh, J D Lu, Anna Wiechowska‐Kozłowska, J Leszczyszyn, Radosław Kempiński, Jarosław Kierkuś, Christopher Ma, T Ritter, B G Feagan, Ş. Targan
出版 2023Artigo -
4
DOP87 The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study Results 由 B G Feagan, B E Sands, Corey A. Siegel, Marla C. Dubinsky, Randy Scott Longman, J Sabinho, O Laurent, Allison Luo, J D Lu, Hieu Nguyen Dinh, F Towfic, A DuVall, M Woyranowski, Houssam A. Kharrat, D P B McGovern
出版 2023Artigo
相關主題
Alternative medicine
Clinical endpoint
Clinical trial
Disease
Gastroenterology
Internal medicine
Medicine
Pathology
Placebo
Ulcerative colitis
Adverse effect
Crohn's disease
Environmental health
Hepatology
Immunology
Inflammatory bowel disease
Lymphoma
Population
Rituximab
Surgery
Surrogate endpoint